No Seismic Shifts As Torrential Rain Dampens JPM Jamboree
Executive Summary
Drug pricing, diversity and US tax reform dominated discussions at JP Morgan. Deals announced at the conference didn't spark much excitement, but attendees were confident that the biopharma sector will still get capital market support.
You may also be interested in...
Biopharma 2018: Is There Still A Place For Pharma In The New Health Care Economy?
2018 will be a time of transition in health care, when biopharma’s counterparts in adjacent industry segments scale up in a radical redesign of their traditional business models. Biopharma is not moving as quickly, and it confronts a strategic dilemma on how to address the prospect of a much more powerful set of rivals in the ongoing battle to own the patient experience in medicine.
Biopharma 2018: Is There Still A Place For Pharma In The New Health Care Economy?
2018 will be a time of transition in health care, when biopharma’s counterparts in adjacent industry segments scale up in a radical redesign of their traditional business models. Biopharma is not moving as quickly, and it confronts a strategic dilemma on how to address the prospect of a much more powerful set of rivals in the ongoing battle to own the patient experience in medicine.
In Vivo's 2017 Deals Of The Year: The Winners Are…
We nominated 15 deals in three categories. You picked the winners.